Interrogation of ERBB2 amplification in breast cancer has led to therapeutic success, but trials of drugs targeting HER2, including trastuzumab, pertuzumab and lapatinib, have yielded poor results in ovarian cancer [54]. Here, ERBB2 is linked to breast carcinoma.